(Nasdaq: GNPX) Profile
OUR NEW PROFILE IS: (NASDAQ: GNPX) ________________________ IN JUNE, THE FDA GRANTED FAST TRACK DESIGNATION FOR THE ACCLAIM-3 TREATMENT COMBINATION OF REQORSA AND TECENTRIQ AS MAINTENANCE THERAPY IN PATIENTS WITH ES-SCLC WHO DID NOT DEVELOP TUMOR PROGRESSION AFTER RECEIVING TECENTRIQ AND CHEMOTHERAPY AS INITIAL STANDARD TREATMENT IN AUGUST, THE FDA GRANTED ORPHAN DRUG DESIGNATION […]
SRFM Profile
OUR NEW PROFILE IS: (NYSE: SRFM) PRO FORMA1 REVENUE, WHICH ASSUMES PRO FORMA OPERATING RESULTS FOR BOTH SURF AIR AND SOUTHERN FOR THE FULL YEAR OF 2023, IN THE RANGE OF $107.5 MILLION TO $112.5 MILLION, AS COMPARED TO $101 MILLION FOR THE FULL YEAR 2022 SURF AIR MOBILITY ENTERS AGREEMENT TO SUPPLY ELECTRIC POWERTRAINS TO KENYA’S LARGEST CESSNA CARAVAN CHARTER OPERATOR Z.BOSKOVIC […]
(Nasdaq: TRNR) Profile
OUR NEW PROFILE IS: (NASDAQ: TRNR) ___________________________________ IN MAY, FORME ANNOUNCED A PARTNERSHIP WITH AETHOS, A HOTEL BRAND WITH LOCATIONS IN PORTUGAL, SPAIN AND ITALY THAT WILL PUT FORME’S CONNECTED FITNESS MIRRORS IN ALL OF ITS HOTELS AND MEMBER CLUBS. ANNUALIZED RECURRING REVENUE PER HOUSEHOLD IN Q1 2023 MORE THAN TRIPLES YOY TO $1,650 LATE LAST YEAR THE COMPANY ANNOUNCED A DISTRIBUTION PARTNERSHIP WITH […]
(NYSE: MAIA) Profile
OUR NEW PROFILE IS: (NYSE AMERICAN: MAIA) ______________________ LEAD CANDIDATE THIO MAINTAINS UNPRECEDENTED DISEASE CONTROL RATES IN PHASE 2 NON-SMALL CELL LUNG CANCER (NSCLC) CLINICAL TRIAL MULTIPLE CLINICAL MILESTONES AHEAD FOR THIO-101 PHASE 2 TRIAL MAIA ENTERS 2024 WITH ROBUST CLINICAL PIPELINE IN MULTIPLE HARD-TO-TREAT CANCER INDICATIONS FDA GRANTS ORPHAN DRUG DESIGNATION TO MAIA BIOTECHNOLOGY […]
(Nasdaq: MODD) Profile
OUR NEW PROFILE IS: (NASDAQ: MODD) MODULAR MEDICAL ANNOUNCES COLLABORATION WITH GLOOKO THERE ARE 1.9 MILLION INDIVIDUALS WITH TYPE 1 DIABETES IN THE US. 100% OF PATIENT POPULATION REQUIRE DAILY INSULIN INJECTION. ONLY 1 OUT OF 3 CURRENTLY USE AN INSULIN PUMP WE HAVE SEEN INSIDERT PURCHASE OVER 575K SHARES IN THE PAST 12 MONTHS WITH ZERO SALES ACCORDING […]
(Nasdaq: LQR) Profile
OUR NEW PROFILE IS: (NASDAQ: LQR) LQR HOUSE REPORTS 458% YOY REVENUE SURGE IN DECEMBER 2023, FUELED BY HOLIDAY ECOMMERCE SUCCESS LQR ANNOUNCES THE REPURCHASE OF 703,798 OF ITS SHARES, REPRESENTING 15% OF ITS TOTAL OUTSTANDING LQR IMPLEMENTED A 1-FOR-60 REVERSE STOCK SPLIT BACK ON NOVEMBER 30, DRASTICALLY REDUCING THE FLOAT INDEX INVESTMENT GROUP ACQUIRES […]
(Nasdaq: COCH) Profile
AS OF SEPTEMBER 30, 2023 THE COMPANY HAD $7.4 MILLION IN AVAILABLE CASH; TOTAL CASH INCLUDING RESTRICTED FUNDS WAS $16.8 MILLION ENVOY MEDICAL BECAME A NASDAQ LISTED COMPANY THROUGH A MERGER WITH ANZU SPECIAL ACQUISITION CORP I, WHICH CLOSED ON SEPTEMBER 29, 2023 THE JOURNAL OF CLINICAL MEDICINE HIGHLIGHTED EARLY SURGICAL EXPERIENCE WITH THE INVESTIGATIONAL ACCLAIM® FULLY IMPLANTABLE COCHLEAR IMPLANT. ACCORDING TO THE […]
(Nasdaq: MYMD) Profile
OUR NEW PROFILE IS: (NASDAQ: MYMD) RA AFFECTS UP TO 14 MILLION PEOPLE AROUND THE WORLD MYMD PHARMACEUTICALS PLANS FDA-CLEARED PHASE 2 CLINICAL TRIAL OF MYMD-1 IN RHEUMATOID ARTHRITIS MYMD PHARMACEUTICALS REPORTS STATISTICALLY SIGNIFICANT POSITIVE TOPLINE PHASE 2 RESULTS FOR NEXT GENERATION ORAL TNF-Α INHIBITOR MYMD-1® IN SARCOPENIA/AGE-RELATED FRAILTY VIEW THE INVESTOR PRESENTATION HERE _______________________________ Hello […]
(Nasdaq: BRSH) Profile
OUR NEW PROFILE IS: (NASDAQ: BRSH) BREAKING NEWS ON FRIDAY: BRUUSH ORAL CARE INC. AND ARRIVE TECHNOLOGY INC. ANNOUNCE AGREEMENT AND PLAN OF MERGER BRUUSH IS ENDORSED BY FAMOUS COMEDIAN KEVIN HART THEY HAVE RECEIVED OVER 3,000 ORGANIC REVIEWS WITH A 90% 5-STAR RATING THEIR RETURN RATE IS LESS THAN 1%, COMPARED TO A U.S. NATIONAL […]
(Nasdaq: MGRX) Profile
OUR NEW PROFILE IS: (NASDAQ: MGRX) 52% OF MEN EXPERIENCE SOME FORM OF ERECTILE DYSFUNCTION THROUGHOUT THEIR LIFE AND THAT TOTAL INCREASES ANYWHERE FROM 5-15% BETWEEN AGES 40 AND 70 MANGOCEUTICALS LAUNCHES MANGORX MEXICO SUBSIDIARY, PAVING THE WAY FOR OVER-THE-COUNTER RETAIL OF ERECTILE DYSFUNCTION LINE OF PRODUCTS IN LATIN AMERICA MGRX EXPERIENCED SEQUENTIAL REVENUE GROWTH […]